These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
144 related items for PubMed ID: 1648976
21. Transfusion of leukoreduced cellular blood components from cytomegalovirus-unscreened donors in allogeneic hematopoietic transplant recipients: analysis of 72 recipients. Narvios AB, de Lima M, Shah H, Lichtiger B. Bone Marrow Transplant; 2005 Sep; 36(6):499-501. PubMed ID: 16044143 [Abstract] [Full Text] [Related]
25. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Vamvakas EC. Transfus Med Rev; 2005 Jul 04; 19(3):181-99. PubMed ID: 16010649 [Abstract] [Full Text] [Related]
29. CMV infections in bone marrow transplanted patients--evaluation of prophylaxis with Cytotect (CMV hyperimmuneglobulin). Zintl F, Färber I, Hermann J, Fuchs D, Prager J, Wutzler P. Folia Haematol Int Mag Klin Morphol Blutforsch; 1989 Jul 04; 116(3-4):557-64. PubMed ID: 2480308 [Abstract] [Full Text] [Related]
30. Cytomegalovirus infections after allogeneic bone marrow transplantation. Winston DJ, Ho WG, Champlin RE. Rev Infect Dis; 1990 Jul 04; 12 Suppl 7():S776-92. PubMed ID: 2173107 [Abstract] [Full Text] [Related]
31. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, Buhles WC, DeArmond B, Meyers JD. N Engl J Med; 1991 Dec 05; 325(23):1601-7. PubMed ID: 1658652 [Abstract] [Full Text] [Related]
32. Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products. Rubie H, Attal M, Campardou AM, Gayet-Mengelle C, Payen C, Sanguignol F, Calot JP, Charlet JP, Robert A, Huguet F. Bone Marrow Transplant; 1993 Mar 05; 11(3):209-14. PubMed ID: 8385522 [Abstract] [Full Text] [Related]
33. Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s. Winston DJ, Gale RP. Bone Marrow Transplant; 1991 Jul 05; 8(1):7-11. PubMed ID: 1655140 [Abstract] [Full Text] [Related]
35. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Przepiorka D, Ippoliti C, Panina A, Goodrich J, Giralt S, van Besien K, Mehra R, Deisseroth AB, Andersson B, Luna M. Bone Marrow Transplant; 1994 Apr 05; 13(4):461-4. PubMed ID: 8019472 [Abstract] [Full Text] [Related]
39. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED, Meyers JD. N Engl J Med; 1986 Apr 17; 314(16):1006-10. PubMed ID: 3007984 [Abstract] [Full Text] [Related]